Skip to content
← Back to News & Views
In the News · Endpoints News · September 10, 2025

Neuro biotech Leal Therapeutics raises $30M Series A

KARV client Leal Therapeutics announces a $30M Series A to advance its neuroscience pipeline.
By Tehya Frank

KARV client Leal Therapeutics, a neuroscience-focused biotech, has announced a $30 million Series A financing to advance its pipeline of precision therapeutics for central nervous system disorders.

Read the full story at Endpoints News.

Health & Wellness
More by Tehya Frank
Recognition
Recognition
Recognition

Alana Abramson and Tehya Frank Named to PRNews Top Women in PR 2026

PRNews honors two of KARV's senior leaders in its 2026 Top Women in PR Awards, recognizing standout women shaping communications across business, policy, and media.
andrew@kelp.agency
In the News
In the News
In the News

KARV Client Dr. Asa Abeliovich Featured in Crain’s Notable Leaders in Healthcare Technology

KARV client Dr. Asa Abeliovich recognized by Crain's New York Business in its Notable Leaders in Healthcare Technology list.
KARV
In the News
In the News
In the News

Leal Therapeutics Inks $30M Series A

Venture Capital Journal covers KARV client Leal Therapeutics' $30 million Series A.
KARV